Sanofi
NASDAQ:SNYDrug Manufacturers - General
-$0.31 today
- Market cap
- $113.15B
- Beta
- 0.28
- P/E (TTM)
- 8.5
- EPS (TTM)
- $8.60
- Dividend yield
- 5.62%
Volume 2.32M
Average 2.78M
SNY Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
SanofiNASDAQ: SNY
Depreciation & Amortization · Q2 FY2026 · quarter ended Jun 2026
Depreciation & amortization growth accelerates
Q2 FY2026 depreciation & amortization of €2.91B rose 65.7% year over year, ahead of the +22.9% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 444.6% from the prior quarter. Over 3 fiscal years it compounded at +22.2% a year.
Context
- Depreciation & amortization amounted to 12.2% of revenue in FY2025, up 4.1 pp from a year earlier.
- Depreciation & amortization increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +65.7% holds above the trailing-twelve-month pace of +22.9%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
EUR · from the cash flow
- Latest · FY2025
- 5.68B EUR
- Year-over-year change
- +58.3%
- 4-year CAGR
- +14.1%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 5.68B | +58.3% |
| FY2024 | 2024-12-31 | 3.59B | -19.0% |
| FY2023 | 2023-12-31 | 4.43B | +42.5% |
| FY2022 | 2022-12-31 | 3.11B | -7.3% |
| FY2021 | 2021-12-31 | 3.35B | — |
Depreciation & Amortization vs competitors
How SNY compares with its peers on the latest reported figures
- Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +22.9% is the 4th highest of 11, against a peer median of -1.7%.
- Depreciation & amortization amounts to 12.0% of revenue for SNY, versus a peer median of 9.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | DKK 27.16B DKK | +69.6% | +44.0% | 8.2% | |
| LTM Jun 2026 | $6.72B USD | +45.9% | +14.3% | 10.1% | |
| LTM Jun 2026 | $6.58B USD | -3.0% | +9.2% | 10.3% | |
| LTM Sep 2026 | $6.41B USD | +29.8% | +3.0% | 10.3% | |
| LTM Jun 2026 | €5.88B EUR | +22.9% | +22.2% | 12.0% | |
| LTM Jun 2026 | $5.34B USD | -11.0% | -7.2% | 9.6% | |
| LTM Jun 2026 | $4.67B USD | -15.5% | +14.8% | 12.2% | |
| LTM Jun 2026 | $3.18B USD | -51.1% | -26.9% | 6.5% | |
| LTM Jun 2026 | $2.76B USD | -0.4% | +9.5% | 9.1% | |
| LTM Jun 2026 | £2.21B GBP | -34.0% | +2.5% | 6.7% | |
| LTM Jun 2026 | $2.1B USD | +10.9% | +9.5% | 2.6% | |
| Peer median (excluding SNY) | — | -1.7% | +9.3% | 9.3% | |
Competitors are the stored peer set for SNY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 6.22B | 7.97B | 5.06B | 5.5B | 5.57B |
| Depreciation & Amortization | 3.35B | 3.11B | 4.43B | 3.59B | 5.68B |
| Deferred Income Tax | (356M) | (529M) | (1.23B) | (802M) | (2.75B) |
| Stock-Based Compensation | 244M | 0 | 0 | 0 | 0 |
| Change in Working Capital | 1.41B | (794M) | 413M | (615M) | 2.03B |
| Accounts Receivables | 185M | (500M) | (472M) | (28M) | (1.36B) |
| Inventory | (357M) | (918M) | (866M) | (477M) | (44.02M) |
| Accounts Payables | 451M | 340M | 258M | 789M | 449.17M |
| Other Working Capital | 1.13B | 284M | 1.49B | (899M) | 2.98B |
| Other Non-Cash Items | (349M) | 771M | 1.59B | 1.42B | 1.61B |
| Operating Cash Flow | 10.52B | 10.53B | 10.26B | 9.08B | 12.13B |
| Capital Expenditures | (2.04B) | (2.1B) | (2.91B) | (3.2B) | (1.99B) |
| Acquisitions (Net) | (5.59B) | (1.34B) | (2.63B) | (2.52B) | 955.91M |
| Purchases of Investments | (311M) | (488M) | (134M) | 0 | (11.37B) |
| Sales of Investments | 718M | 0 | 0 | 0 | 0 |
| Other Investing Activities | (68M) | 1.86B | (533M) | 1.35B | 11.74B |
| Investing Cash Flow | (7.3B) | (2.08B) | (6.2B) | (4.41B) | (2.76B) |
| Debt Repayment | (2.8B) | (1.23B) | (3.14B) | (894M) | 2.07B |
| Common Stock Issued | 186M | 188M | 195M | 187M | 199.76M |
| Common Stock Repurchased | (382M) | (497M) | (593M) | (302M) | (5.68B) |
| Dividends Paid | (4.01B) | (4.17B) | (4.45B) | (4.7B) | (5.39B) |
| Other Financing Activities | (48M) | (111M) | (63M) | (50M) | (472.87M) |
| Financing Cash Flow | (7.06B) | (5.82B) | (8.05B) | (5.76B) | (9.26B) |
| Effect of Forex Changes | 15M | 8M | (32M) | (13M) | 862.16M |
| Net Change in Cash | (3.82B) | 2.64B | (4.03B) | (1.27B) | 970.51M |
| Free Cash Flow | 8.48B | 8.42B | 7.35B | 5.89B | 10.14B |
Sanofi
NASDAQ:SNY
Intrinsic Alpha fair value
Locked
Current Price
$47.12
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.